These data are consistent with previous observations that markers associated with the IL-23/IL-17 pathway (ie, IL-17A, IL-17F, IL-22, and CCL22/MDC) are elevated in serum from patients with psoriasis (Fotiadou et al, 2015; Suárez-Fariñas et al, 2012). Here, CCL22 is linked to psoriasis.